Meta AnalysisID 1349
花青素作为阿尔茨海默病的治疗药物：临床前证据的系统评价
CRD42021272972
How far the natural pigment anthocyanin is effective in mitigating the signs and symptoms associated with Alzheimer's Disease? Context and rationale Alzheimer’s disease (AD), the most common form of dementia, is a progre
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1349
- Evidence Id
- 9907
- Core Evidence Id
- 9907
- Source Meta Analysis Id
- 1309
- Herb2 Meta Analysis Id
- HBMA001309
- Crd Id
- CRD42021272972
- Title
- Anthocyanin as a therapeutic in Alzheimer's Disease: A systematic review of preclinical evidence.
- Review Question
- How far the natural pigment anthocyanin is effective in mitigating the signs and symptoms associated with Alzheimer's Disease? Context and rationale Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. It is a complex and an age-related brain disease which is induced by the accumulation of amyloid beta (Aβ) and neuroinflammation. The development of AD leads to the progressive decline in cognitive function and ultimately lead to death. It is estimated that there are approximately 44 million people worldwide living with Alzheimer’s disease and only few get diagnosed. Anthocyanins, a class of water soluble flavonoids extracted from plants like berries and soybean seed, have been shown to display obvious anti-oxidative, anti-inflammatory, and anti-apoptotic activities. They are recommended as a supplementation for prevention and/or treatment of disorders ranging from cardiovascular disease, metabolic syndrome, and cancer. In the central nervous system (CNS), anthocyanins and its major component cyanidin-3-O-glucoside have been reported to produce preventive and therapeutic activities in Alzheimer's disease. Many studies in the literature have focused on the therapeutic potential of anthocyanin aimed at the prevention of neurodegenerative diseases. Considering the growing number of studies that provide evidence of the health benefits of ANT, especially on Alzheimer's Disease, and lack of a systematic review or meta analysis on this topic, this systematic review will investigate the effect of anthocyanin on protecting learning and memory ability by systematically analyzing preclinical studies.
- Study Type Included
- Inclusion criteria: Pre-clinical research studies Exclusion criteria: 1. Not an animalstudy 2. Clinical studies 3. Not an Alzheimer's disease model 4. In vitro Studies 5. In silico studies
- Condition Being Studied
- Participant
- Animal
- Inclusion criteria: 1. Pre-clinical studies 2. Alzheimer's Disease model 3. Both gender 4. All the age groups Exclusion criteria: 1. Clinical studies 2. Not an Alzheimer's disease model 3. In vitro Studies 4. In silico studies
- Human Disease Modelled
- Alzheimer's Disease
- Intervention
- Inclusion criteria: Anthocyanin pigment from any natural source, synthetic anthocyanins, Anthocyanin rich extracts, crude extracts rich in anthocyanin, Anthocyanin isolates, commercially available anthocyanin, all types of anthocyanins available in nature in any dose, dosage form, route of administration, and frequency. Exclusion criteria: Any flavonoid other than anthocyanin, any pigment other than anthocyanin, combination therapies.
- Comparator Control
- Inclusion criteria: studies with both standard/conventional drug therapy (positive control) and negative control groups with or without normal control Exclusion criteria: Groups having comorbidities
- Main Outcome
- Outcome Measure
- Inclusion criteria: Study having outcome measures of any of the following Behavioral assessment, beta-amyloid levels, inflammatory markers, neuroprotective markers, antioxidant levels, oxidative markers, acetylcholinesterase levels, apoptotic markers, butyrylcholinesterase levels, histopathology of the brain, electrophysiology of brain, any other neurodegenerative markers. Exclusion criteria: Study having outcome measured other than that of neurodegeneration or Alzheimer's disease or dementia will be excluded.
- Additional Outcome
- Study Method
- Keyword
- Alzheimer Disease; Animals; Anthocyanins
- Contact
- SWATHI SURESH [email protected]
- Organisational Affiliation
- SRM INSTITUTE OF SCIENCE AND TECHNOLOGY, POTHERI-603203, CHENGALPATTU, TAMILNADU, INDIA https://www.srmist.edu.in/
- Funding Source
- This study is not funded by any sources/sponsors
- Other Selection Criteria
- Review articles, Conference abstracts, Studies not in English language will be excluded.
- Final Publication
- Swathi Suresh, Rukaiah Fatma Begum, Ankul Singh S, Chitra V, Anthocyanin as a therapeutic in Alzheimer's disease: A systematic review of preclinical evidences, Ageing Research Reviews, Volume 76, 2022, 101595, ISSN 1568-1637, https://doi.org/10.1016/j.arr.2022.101595. https://doi.org/10.1016/j.arr.2022.101595
- Same Topic Review
- Published Protocol
- Review Type
- Pre-clinical animal intervention review
- Language
- English
- Country
- India
- Review Stage
- Review Completed published
- First Submission Date
- 2021-08-11
- Registration Date
- 2021-10-30
- Anticipated Start Date
- 2021-08-09
- Anticipated Completion Date
- 2022-01-12
- Title Cn
- 花青素作为阿尔茨海默病的治疗药物：临床前证据的系统评价
- Title En
- Anthocyanin as a therapeutic in Alzheimer's Disease: A systematic review of preclinical evidence.
- Bilingual Status
- complete